An open-label pilot study of pregabalin pharmacotherapy for alcohol use disorder.

The American Journal of Drug and Alcohol Abuse
John J MarianiFrances R Levin

Abstract

Background: There is a need for alcohol use disorder (AUD) pharmacotherapy that can be administered to actively drinking outpatients. Pregabalin, a gabapentoid anticonvulsant, has preliminary evidence supporting effects on alcohol withdrawal and AUD.Objectives: To evaluate the safety, tolerability, and optimal dosing of pregabalin for treating AUD.Methods: In an open-label, 8-week, outpatient trial of eighteen adults (nine women) with AUD, participants were titrated to 600 mg/day (or the maximum tolerated dose) over 3 weeks and then maintained for 5 weeks.Results: The majority (11/14, 78.6%) of participants with at least one-week of medication exposure achieved a maximum dose of 600 mg/day. Mean retention was 6.8 weeks (SD = 2.6). Eighty percent (12/15) of participants with post-enrollment data reported any adverse effects during the trial; and for those reporting adverse effects the most common were drowsiness (33.3%, 4/12), and fogginess (25%, 3/12), dizziness (25%, 3/12), and insomnia (25%, 3/12). Two participants discontinued study medication due to adverse effects and one had a dose reduction. Mean Heavy Drinking Days (HDD)/week decreased significantly by 3.43 days (SD = 2.47; median (IQR) = 4.00 (1.00 to 5.50)); Wilcoxon ...Continue Reading

References

Jun 23, 2004·Journal of Clinical Psychopharmacology·Atul C PandeJohn L Werth
Aug 25, 2004·The Journal of Clinical Psychiatry·Stephen M Stahl
Oct 15, 2005·Journal of Studies on Alcohol. Supplement·Bankole A JohnsonJohn D Roache
Oct 15, 2005·Journal of Studies on Alcohol. Supplement·Helen M PettinatiBruce J Rounsaville
Apr 26, 2006·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Howard C BeckerLynn M Veatch
Dec 7, 2007·The Journal of Clinical Psychiatry·Fernando A Furieri, Ester M Nakamura-Palacios
Jun 11, 2008·Alcoholism, Clinical and Experimental Research·Kirk J BrowerRobert A Zucker
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Apr 7, 2009·Journal of Psychopharmacology·G MartinottiL Janiri
Jun 3, 2009·Alcoholism, Clinical and Experimental Research·Hugh MyrickCarrie L Randall
Feb 12, 2010·Journal of Clinical Pharmacology·Howard N BockbraderDavid L Wesche
Sep 8, 2010·Clinical Pharmacokinetics·Howard N BockbraderPaula Burger
Jan 5, 2012·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Anna FörgChristian A Müller
Nov 6, 2013·JAMA Internal Medicine·Barbara J MasonAdnan Begovic
May 7, 2014·Alcoholism, Clinical and Experimental Research·Janet C BlodgettJohn W Finney
May 15, 2015·The Annals of Pharmacotherapy·Jonathan G LeungKathryn M Schak
Jun 24, 2018·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mimi PierceWim van den Brink
Sep 1, 2018·JAMA : the Journal of the American Medical Association·Henry R Kranzler, Michael Soyka
May 12, 2019·Addiction·Henry R KranzlerEmily E Hartwell

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The American Journal of Psychiatry
Atul C PandeMaria Liu-Dumaw
Nöro Psikiyatri Arşivi
Mehmet Bülent Sönmez
Revue de l'infirmière
Corinne Taéron
Nature Reviews. Drug Discovery
Robert H Dworkin, Peter Kirkpatrick
© 2021 Meta ULC. All rights reserved